Drug Trial Radar · NCT03669588
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Last checked: Nov 20, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
167
Actual
Start
Aug 22, 2018
Primary completion
Apr 6, 2020
Study completion Apr 6, 2020
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Sep 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Conditions
- Generalized Myasthenia Gravis
Interventions
ARGX-113Biological
Intravenous administration of ARGX-113
PlaceboBiological
Intravenous administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive PopulationTime frame: Baseline up to Day 63 (end of TC1)
Locations
66 sites in 16 countries. Site status is shown where the registry gives one.
Investigator Site 29
Phoenix, Arizona
Investigator Site 66
Carlsbad, California
Investigator Site 5
Los Angeles, California
Investigator Site 49
Los Angeles, California
Investigator Site 18
Orange, California
Investigator Site 40
Palo Alto, California
Investigator Site 59
San Francisco, California
Investigator Site 58
Aurora, Colorado
Investigator Site 34
Jacksonville, Florida
Investigator Site 4
Tampa, Florida
Investigator Site 30
Springfield, Illinois
Investigator Site 25
Iowa City, Iowa
Investigator Site 21
Kansas City, Kansas
Investigator Site 27
Boston, Massachusetts
Investigator Site 48
Detroit, Michigan
Investigator Site 53
Buffalo, New York
Investigator Site 3
Chapel Hill, North Carolina
Investigator Site 20
Cleveland, Ohio
Investigator Site 9
Portland, Oregon
Investigator Site 17
Charleston, South Carolina
Investigator Site
Cordova, Tennessee
Investigator Site 44
Houston, Texas
Investigator Site 6
San Antonio, Texas
Investigator Site 2
Charlottesville, Virginia
Investigator Site 16
Seattle, Washington
Investigator Site 11
Edegem, Belgium
Investigator Site 8
Ghent, Belgium
Investigator Site 38
Edmonton, Alberta, Canada
Investigator Site 24
Toronto, Ontario, Canada
Investigator Site 22
Montreal, Quebec, Canada
Investigator Site 32
Brno, Czechia
Investigator Site 35
Ostrava-Poruba, Czechia
Investigator Site 51
Prague, Czechia
Investigator Site 36
Aarhus, Denmark
Investigator Site 15
Copenhagen, Denmark
Investigator Site 13
Bordeaux, France
Investigator Site 52
Marseille, France
Investigator Site 46
Tbilisi, Georgia
Investigator Site 45
Tbilisi, Georgia
Investigator Site 47
Tbilisi, Georgia
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.